Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 1.00 |
| ▸ | DRD2 | P14416 | 8/20 | 1.00 |
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 5/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | GOT1 | P17174 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161659 | 0.85 | DRD2 (0.73) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL2161656 | 0.85 | DRD2 (0.73) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL2161683 | 0.84 | GAA (1.00) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL2161629 | 0.83 | DRD2 (0.70) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL13493196 | 0.82 | DRD2 (0.70) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL12401748 | 0.82 | DRD2 (0.69) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL7732059 | 0.82 | DRD2 (0.69) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL2162489 | 0.82 | GAA (0.74) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL23102103 | 0.81 | DRD2 (0.68) | DRD4DRD2DRD3GAAMAPT | |
| SCHEMBL2162396 | 0.81 | GAA (1.00) | DRD4DRD2DRD3GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | claimed |
| EP-2149373-A1 | 5HT7 receptor ligands and compositions comprising the same | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | claimed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| WO-2011088838-A1 | NOVEL 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACEPHENANTHRYLENE DERIVATIVES AS DOPAMINE D2 LIGANDS | H. LUNDBECK A/S (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2010012817-A2 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| EP-2149373-A1 | 5HT7 receptor ligands and compositions comprising the same | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149373-A1 | 5HT7 receptor ligands and compositions comprising the same | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
| CN-1321110-C | 4-piperazinyl indole derivatives having 5-HT6 receptor affinity | HOFFMANN LA ROCHE CO LTD (CH) | 2007-06-13 | — | — | CN | disclosed |
| EP-1335722-B1 | INDOLYL-SULFONYL- COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-30 | — | — | EP | disclosed |
| EP-1401812-B1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | EP | disclosed |
| CN-1694866-A | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | CN | disclosed |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| US-6790848-B2 | TREATING CENTRAL NERVOUS SYSTEM OR GASTROINTESTINAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-14 | — | — | US | disclosed |
| EP-1401812-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102774-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR3A | DRD4 48/4885DRD2 35/4885DRD3 33/4885 |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SLC18A2, CNR2, TPH2 | DRD4 167/4885DRD2 98/4885DRD3 126/4885 |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | HTR7, HTR1A, HTR6 | DRD4 70/4885DRD2 43/4885DRD3 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.